By targeting AR signaling pathways, honokiol impairs AR-mediated transcriptional activity, enhancing the efficacy of existing prostate cancer therapies and offering potential applications for treating castration-resistant prostate cancer (CRPC). The gene discussed is AR; the disease is prostate carcinoma.